Browsing Tag
camizestrant
3 posts
Guardant360 enters a new breast cancer workflow built on testing every three months
Guardant Health has secured FDA approval for Guardant360 CDx as the companion diagnostic for AstraZeneca’s Etcamah, introducing repeated liquid-biopsy testing during first-line metastatic breast cancer therapy.
FDA advisers voted 6-3 against AstraZeneca’s breast cancer strategy. The drug was just approved anyway
The U.S. Food and Drug Administration has granted accelerated approval to AstraZeneca’s Etcamah after a Phase III trial showed a 56% reduction in progression or death, creating the first U.S. cancer treatment strategy triggered by a resistance mutation found in blood before imaging shows disease progression.
Why clinicians and regulators are closely watching AstraZeneca’s rare disease and solid tumor pipeline strategy
Why AstraZeneca’s ASCO 2026 rare disease and solid tumor pipeline strategy is drawing major clinical and regulatory attention. Read more.